GSK wins jury verdict in Illinois ranitidine cancer case

GSK

GSK plc has welcomed today’s jury verdict in the Joiner case in Illinois state court finding in GSK’s favour.

·   Jury in Joiner case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer

·   Verdict is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer

·   GSK will continue to vigorously defend itself against all other claims

This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine. GSK will continue to vigorously defend itself against all other claims.

Prior to this verdict, the court rejected the Plaintiff’s ability to request punitive damages.

Share on:

Latest Company News

GSK filing accepted by EMA for Bexsero booster label update

GSK says the EMA has accepted a submission to update Bexsero’s label to include a single-dose booster for older previously vaccinated individuals.

GSK reports positive interim AZUR-1 results for Jemperli in rectal cancer

GSK has reported positive interim AZUR-1 results for Jemperli in dMMR/MSI-H locally advanced rectal cancer, with the study meeting its primary objective.

GSK gains US FDA approval for oral cUTI antibiotic Utebzi

GSK has secured US FDA approval for Utebzi, an oral carbapenem antibiotic for certain adult patients with complicated urinary tract infections.

GSK receives orphan designations for momelotinib in VEXAS syndrome

GSK has received orphan drug designations for momelotinib in the US and EU for VEXAS syndrome, with phase II/III development planned.

GSK to acquire Biotech Growth Trust portfolio company Nuvalent for $10.6bn

Biotech Growth Trust notes GSK’s agreed $10.6bn cash acquisition of Nuvalent, a BIOG portfolio company focused on targeted cancer therapies.

Japan expands approval of GSK’s Arexvy to at-risk adults aged 18–49

GSK says Japan has expanded Arexvy eligibility to adults aged 18–49 at increased risk of RSV disease, including immunocompromised patients.

    Search